Metastatic Hormone and Her-2 Positive Breast Cancer: A Community Approach
Journal Title: Open Access Journal of Oncology and Medicine - Year 2018, Vol 2, Issue 1
Abstract
Metastatic hormone-receptor and HER-2 positive (triple-positive) breast cancer provides a treatment dilemma for clinicians. The current guidelines offer a variety of options in the first and second line for metastatic breast cancer. A tailored treatment approach is needed for the triple-positive metastatic breast cancer population. Objective To trend the therapeutic treatment selections for patients with metastatic, triple-positive breast cancer at a single, community practice. Methods: The Abington Jefferson Health Tumor Registry and electronic medical records systems were used to retrospectively identify patients with hormone and HER-2 positive metastatic disease who were treated at Abington Jefferson Health between 2010-2016. Results: It was found that there was variability across our population in the choice of what therapy was chosen for first, second and fourth line of treatment. The majority of patients (12 out of 15) received combination therapy with trastuzumab. In the second line, 7 out 8 patients received trastuzumab as part of their treatment regimen. In the third line, all 3 patients received trastuzumab emtansine as part of their therapy regimen. For patients who were able to survive until the fourth line and beyond, several other treatments were used. Limitations: A small sample size is the major limitation in this study. Conclusion: Although HR+/ Her2+ (triple positive) cancer cell type represents a subset of patients with metastatic breast cancer, there is a general lack of consensus on how to best treat this patient population. More research needs to be conducted in order for community Oncologic practitioners to be able to better coordinate care for patients with triple positive, metastatic breast cancer.
Authors and Affiliations
Ida Micaily, Lakshmi Kolandra, Shahrzad Abdollahi, Anthony Scarpaci
Keywords
Related Articles
- EP ID EP587898
- DOI 10.32474/OAJOM.2018.02.000127
- Views 94
- Downloads 0
Pilomatricoma Localized in the Arm: A Rare Case Report
A pilomatricoma is a rare, benign skin tumour originating from the hair follicle cells. It accounts for 0.15 of skin tumours is. It usually involves the head and neck region. The definitive diagnosis is based on histolog...
Targeting the Immune Checkpoint in Cancer: Is This a Viable Treatment Option for AML?
The immune suppressive mechanisms displayed by malignant cells are considered a central process in the pathogenesis of cancer. Research in this area has gained significant momentu mover the past 20 years, with several im...
Checkpoint Inhibitors in Squamous Non-Small Cell Lung Cancer (NSCLC)
Checkpoint inhibitors have demonstrated efficacy in squamous NSCLC with tolerable toxicity profile. They are used as a monotherapy, in combination with chemotherapy or following chemo-radiotherapy as a first line, second...
Traditional Medicine in Contextual African Society: On-Going Challenges
The role of traditional medicine in contextual African society cannot be overemphasized. Due to the less financial implication on the part of patients(s) patronizing the medicine to treat a particular ailment. In recent...
Identifying Different Risk Factors of Cervical Cancer in Rural Women Population of Lucknow West, India: A 5 Years Study
Carcinoma cervix is a major health problem faced by Indian women and though its incidence has declined in urban population in recent years but in the rural India where 70% of the people dwell, cervical cancer still remai...